South Korea's bio is ready to leap into new business model

JPMorgan Healthcare Conference Shows Power Of S. Korean Bio

(KOREA = KTN) Reporter Kim Do-hyung = The Korea Bio Association participated in the 'JP Morgan Healthcare Conference (JPM 2025), a pharmaceutical bio investment conference held in San Francisco, USA from January 13 to 16 and revealed the Korean bio industry's presence on the global stage.

In particular, the 5th Global IR@JPM held on the 14th was held at the Nasdaq Antraf Renewal Center, where IR presentations and Q&A sessions of 10 bio startups from Korea and abroad were held. Not only JPMorgan organizers, but also a number of global investors, including Johnson & Johnson Innovation, Pfizer Ignite and Korea Investment Partners, participated in the event, showing high interest.

Six domestic biotech companies, including △ Appclone △ Arteon Bio △ Senix Biotech △ Mediwale △ Noveltynowability △ VS Farmtech, were included in the participating companies. They each presented innovative technologies and business models, including new antibody drugs, AI-based physical disease prediction technology, and radiation therapy.

"Global investors were impressed by the innovative technologies and business strategies of domestic companies," said Hwang Joo-ri, head of the Korea Bio Association's exchange and cooperation division. "We expect more companies to receive attention next year."

Global Networking and Panel Discussion – Discussing the Future of the Bio-Industry

In addition, more than 700 global bio industry officials participated in the "Korea Night" event to help expand the network of Korea Bio. At the event, a panel discussion was held under the theme of "Investment Beyond Borders – Investment Outlook for Bio Industry in 2025."

The discussion was attended by Jeff Kranmer, editor-in-chief of BioCentury, Andre Adonian of flagship Pioneering, and Amit Kakkar of Novo Holdings. They discussed the investment environment of the bio industry, ways to overcome bottlenecks, and the need for a new business model.

'New-Co Model' – Presenting the success strategy of bio startups

On the last day, a panel discussion on the 'New-Co Model' dealing with the latest deal trends was held. Experts who participated in the discussion emphasized the importance of rapid failure, concentrated technology development, and external partnerships as requirements for the success of bio startups.

Candid Therapeutics and Epimap Biotherapeutics recently drew attention by presenting a successful collaborative model through the collaboration of the new T-cell Engager program.

Korean bio companies are recognized as key partners in the global bio industry at the JPMorgan Conference for their technological prowess and potential for collaboration. The Korea Bio Association plans to use this opportunity to boost the status of Korean bio through more active international exchange and investment.

<저작권자(c)한국유통신문. 무단전재-재배포 금지> 

 기사제보 및 사회적 공헌활동 홍보기사 문의: 010-3546-9865, flower_im@naver.co

검증된 모든 물건 판매 대행, 중소상공인들의 사업을 더욱 윤택하게 해주는